Table 1.
Demographic, Clinical, and Maternal of Children Whose Stool Specimens Did or Did Not Contain Ciprofloxacin-Resistant Escherichia coli
| Characteristic | Ciprofloxacin-Resistant E. coli in Stools |
P Value | |
|---|---|---|---|
| Present in ≥1 Tested Sample (n = 15) | Absent From All Tested Samples (n = 65) | ||
| Gestational age at birth, wk | 36 (34–36) | 37 (36–37) | .06 |
| Birth weight, g | 2455 (2325–2583) | 2693 (2393–3008) | .13 |
| Day of life discharged home after birth | 10 (4–13) | 4 (2, 5) | .002 |
| Male sex | 11 (73) | 30 (45) | .09 |
| African American/White | 4 (27) | 6 (9) | .09 |
| Hispanic/not Hispanic | 1 (7) | 4 (7) | 1.0 |
| Monozygotic:dizygotic | 8 (53) | 34 (53) | 1.0 |
| Vaginal birth | 2 (13) | 27 (42) | .07 |
| Maternal perinatal antibioticsa | 14 (93) | 52 (80) | .45 |
| Antibiotics early in lifeb | 6 (40) | 14 (22) | .18 |
| Day of life of first positive specimen | 341 (49–641) | NA | |
| Specimens studied per subject, no. | 22 (15–26) | 24 (21–28) | .1 |
| Specimens positive/tested, no. | 43/299 (26.9) | 0/1514 (0) | |
| Mothers with positive specimens | 8 (53) | 4(6) | .0001 |
| Day of life when final specimen submitted | 681 (624–1060) | 912 (694–1129) | .21 |
| Acid suppression early in lifec | 2 (13) | 12 (18) | 1.0 |
| Exclusively breastfedd | 0 (0) | 10 (15.4) | .19 |
| Exclusively formula fedd | 6 (40) | 16 (24.6) | .34 |
| Combined breastfed and formula fedd | 9 (60) | 39 (60) | 1.0 |
Data are median (interquartile range) or no. (%) of children, unless otherwise indicated.
Abbreviation: NA, not applicable.
a Defined as any perinatal antibiotics administered to the mother within 7 days of birth.
b Defined as antibiotics administered to children during the first 2 weeks of life.
c Defined as proton-pump inhibitors, H2-blockers, or cytoprotective agents administered to children during the first 2 months of life.
d Defined as postdischarge feeds during the first 2 months of life.